Addition of sodium glucose cotransporter 2 (SGLT2) inhibitor to glucagon-like peptide-1 (GLP-1) receptor agonist therapy in obese people with Type 2 diabetes and suboptimal glycaemic control

被引：0
|
作者：
Curtis, L. R. [1 ]
Walker, J. I. [1 ]
Knott, J. [1 ]
Partridge, H. L. [1 ]
机构：
[1] Royal Bournemouth & Christchurch Hosp NHS Fdn Tru, Diabet & Endocrine Ctr, Bournemouth, Dorset, England
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P529
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [1] Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control
    Curtis, Louise
    Humayun, Malik Asif
    Walker, James
    Hampton, Kerri
    Partridge, Helen
    PRACTICAL DIABETES, 2016, 33 (04) : 129 - 132
  • [2] Additive weight loss effect with a combination of an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) agonist in Type 2 diabetes
    Mcgovern, A. P.
    Dutta, N.
    Watters, K.
    Munro, N.
    Feher, M.
    DIABETIC MEDICINE, 2015, 32 : 2 - 3
  • [3] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [4] GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes
    Li, Piaopiao
    Li, Zhiyan
    Staton, Elizabeth
    Umpierrez, Guillermo E.
    Davis, Georgia
    Shao, Hui
    Pasquel, Francisco J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [5] Glucagon-like peptide-1 (GLP-1) in obese subjects with and without type 2 diabetes
    Rotella, CM
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Messeri, G
    Mannucci, E
    DIABETES, 2000, 49 : A1 - A1
  • [6] Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease
    Mehta, Sneha S.
    Surapaneni, Aditya L.
    Pandit, Krutika
    Xu, Yunwen
    Horwitz, Leora
    Blecker, Saul
    Blum, Matthew F.
    Chang, Alexander R.
    Shin, Jung-Im
    Grams, Morgan E.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36 (02): : 290 - 292
  • [7] Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
    Ng, Elisabeth
    Shaw, Jonathan E.
    Wood, Anna
    Maple-Brown, Louise J.
    Hare, Matthew J. L.
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (07) : 513 - 518
  • [8] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712
  • [9] Efpeglenatide Glucagon-like peptide 1 (GLP-1) receptor agonist Treatment for type 2 diabetes
    Reid, J.
    Rana, K.
    Segel, S. A.
    Sheikh-Ali, M.
    Choksi, R. R.
    Goldfaden, R. F.
    DRUGS OF THE FUTURE, 2019, 44 (06) : 435 - 441
  • [10] REAL-WORLD COMPARISON OF ADHERENCE AND PERSISTENCE BETWEEN GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1) AND SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2) IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Risebrough, N.
    Yu, X.
    Edwards, A.
    Shen, Y.
    Hunger, M.
    Lawrence, A.
    VALUE IN HEALTH, 2024, 27 (06) : S401 - S401
12345